SS-31 peptide benefits include mitochondrial energy support and reduced oxidative stress in research. Learn what studies show about dosing and safety.
SS-31 peptide, also known as elamipretide, is a synthetic four-amino-acid peptide studied for its ability to concentrate inside mitochondria and protect a lipid called cardiolipin. The most commonly reported SS-31 peptide benefits in published research are improved mitochondrial energy output, lower oxidative stress, and better function in energy-hungry tissues such as heart muscle, kidney, and skeletal muscle. SS-31 is not FDA-approved for human use, so these findings describe experimental results rather than an established therapy.
What Is SS-31 Peptide?
SS-31 is a small synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. It was designed to target the inner mitochondrial membrane, where most of a cell's ATP is produced.
Its proposed mechanism is unusual. Instead of acting on a receptor, SS-31 binds cardiolipin, a phospholipid that helps shape and stabilize the electron transport chain. When cardiolipin is oxidized, mitochondria become inefficient and leak reactive oxygen species. Protecting cardiolipin is the mechanism researchers credit for most reported effects.
For anyone asking what is ss-31 peptide used for, the honest answer is that it is a research compound explored in heart failure, rare mitochondrial disease, kidney injury, and age-related eye conditions.
Potential SS-31 Peptide Benefits Reported in Research
Most evidence comes from animal models, cell cultures, and small human trials. Results look promising in some areas and mixed in others.
- Mitochondrial energy production: Preclinical studies show restored ATP synthesis and reduced reactive oxygen species in stressed cells.
- Cardiac function: Infusion studies in heart failure patients reported short-term improvements in cardiac performance, although larger trials did not reach their primary endpoints.
- Skeletal muscle performance: In primary mitochondrial myopathy, a six-month trial of daily subcutaneous elamipretide missed its primary six-minute walk endpoint, while some secondary and patient-reported measures suggested benefit.
- Kidney tissue: Animal models of ischemia-reperfusion injury show less tubular damage and faster recovery of kidney function.
- Eye tissue: A phase 2 trial in dry age-related macular degeneration reported improved visual acuity in some participants receiving daily injections.
- Barth syndrome: In a small open-label study, patients with this rare genetic disorder showed improvements in exercise tolerance and heart measurements.
Interest from fitness communities has grown faster than the evidence. Most performance claims trace back to animal studies or to patients with diagnosed mitochondrial disease, not to healthy athletes. Researchers examining SS-31 in healthy adults have mainly measured pharmacokinetics and tolerability, not gains in strength or endurance.
SS-31 Peptide Dosing Used in Studies
Doses are reported in milligrams per kilogram or as fixed subcutaneous milligrams, and every published protocol was supervised by clinicians. Anyone describing one number that fits all people ignores how widely the numbers vary by condition.
| Research setting | Reported dose | Route | Frequency |
|---|---|---|---|
| Early pharmacokinetic studies in healthy adults | Single doses up to 0.6 mg/kg | Intravenous | One-time dose |
| Heart failure infusion studies | 0.05 to 0.25 mg/kg per hour | Intravenous infusion | Four-hour infusion |
| Barth syndrome (TAZPOWER) | 0.25 mg/kg per hour, then 40 mg | IV, then subcutaneous | Daily |
| Primary mitochondrial myopathy (MMPOWER-3) | 40 mg | Subcutaneous | Once daily |
These figures summarize published protocols and are not a recommendation. Any ss-31 peptide dosing protocol used in a trial came with monitoring, lab work, and stopping rules. Those safeguards are part of the treatment, not optional extras.
SS-31 Peptide Benefits and Side Effects
Across human trials, the most common complaints were mild: injection site reactions, headache, nausea, and dizziness. No serious drug-related safety signal has been established in short-term studies.
Two caveats matter. Most trials enrolled people with serious disease and followed them for months rather than years, so long-term safety remains unknown. Research peptides sold online are also not produced under pharmaceutical manufacturing standards, which creates purity and dosing accuracy problems that have nothing to do with the molecule itself.
The full picture of ss-31 peptide benefits and side effects is still being characterized, so anyone considering it should speak with a healthcare professional instead of relying on forum reports.
Is SS-31 Available for Purchase?
Elamipretide has not been approved by the FDA, and it is not legally sold as a dietary supplement or a prescription drug. Products labeled SS-31 are marketed as research chemicals, which means they are not intended for human consumption.
If you search ss-31 peptide buy online, you will find vendors offering vials with purity certificates. Quality varies widely, and third-party testing is often incomplete. Sites listing ss 31 peptide for sale online rarely disclose synthesis methods, endotoxin levels, or cold-chain handling.
Laboratories that need pharmaceutical-grade material typically obtain it through clinical trial programs or licensed suppliers, not consumer storefronts.
How SS-31 Compares With Other Research Peptides
SS-31 is frequently mentioned alongside other mitochondria-focused compounds, but the mechanisms are different.
| Peptide | Primary target | Main research focus | FDA status |
|---|---|---|---|
| SS-31 (elamipretide) | Cardiolipin on the inner mitochondrial membrane | Mitochondrial dysfunction, heart failure, Barth syndrome | Not approved |
| MOTS-c | AMPK signaling and metabolic regulation | Metabolism, insulin sensitivity, exercise capacity | Not approved |
| BPC-157 | Angiogenesis and tissue repair pathways | Tendon, gut, and muscle healing models | Not approved |
No peptide in this group is FDA-approved for human use in the United States.
Bottom Line on SS-31 Peptide Benefits
SS-31 targets a real and well-studied mechanism, and early human data suggest possible benefits for mitochondrial function, muscle performance, and select cardiac and eye conditions. Larger trials have also produced disappointing primary endpoints, which is why elamipretide remains experimental.
If a clinician ever prescribes this compound, the dose should come from that clinician. Until then, treat bold marketing claims with skepticism and prioritize products and protocols that have regulatory oversight.
Frequently Asked Questions
What is SS-31 peptide used for?
SS-31 is a research peptide studied for mitochondrial dysfunction, heart failure, Barth syndrome, primary mitochondrial myopathy, kidney injury, and dry age-related macular degeneration. It is not FDA-approved for any human use, so it is only available through research and clinical trial settings.
Is SS-31 peptide FDA approved?
No. Elamipretide has not received FDA approval for any indication as of now. Several late-stage trials missed their primary endpoints, and the compound remains investigational.
What are the side effects of SS-31 peptide?
In human trials, reported side effects were mostly mild and included injection site reactions, headache, nausea, and dizziness. Long-term safety data are limited because most studies lasted only weeks to months.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.